Specify a stock or a cryptocurrency in the search bar to get a summary
Clinuvel Pharmaceuticals Ltd
CLVLYClinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia. Address: 535 Bourke Street, Melbourne, VIC, Australia, 3000
Analytics
WallStreet Target Price
42.09 AUDP/E ratio
20.7429Dividend Yield
0.37 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CLVLY
Dividend Analytics CLVLY
Dividend growth over 5 years
150 %Continuous growth
2 yearsPayout Ratio 5 years average
8 %Dividend History CLVLY
Stock Valuation CLVLY
Financials CLVLY
Results | 2019 | Dynamics |